Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Aadi Bioscience, Inc. (ARPO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/09/2023 8-K Quarterly results
Docs: "Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update"
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/10/2023 8-K Quarterly results
Docs: "Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial"
03/28/2023 8-K Quarterly results
03/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Aadi Bioscience Announces Leadership Transition"
01/23/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
12/07/2022 8-K Quarterly results
11/25/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
09/22/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
06/29/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/17/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement, by and between the Company and Cowen and Company, LLC",
"Opinion of Wilson Sonsini Goodrich & Rosati P.C"
03/17/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update"
01/19/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
11/23/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Aadi Bioscience Announces FDA Approval of its First Product FYARRO ™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor"
11/10/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update"
11/01/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer"
09/20/2021 8-K Quarterly results
09/13/2021 8-K Quarterly results
09/03/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
08/26/2021 8-K Acquisition/merger/asset purchase announced, Entered into consulting agreement, Resignation/termination of a director
Docs: "Amended and Restated Certificate of Incorporation of the Company, filed August 26, 2021 (filed herewith)",
"Amended and Restated Bylaws of the Company, as currently in effect (filed herewith)",
"Contingent Value Rights Agreement dated August 26, 2021, by and between Aerpio Pharmaceuticals, Inc., Cheryl Cohen, as Holder Representative, and American Stock Transfer & Trust Company, LLC, as Rights Agent (filed herewith)",
"Registration Rights Agreement, by and between Aadi Bioscience, Inc. (formerly known as Aerpio Pharmaceuticals, Inc.) and certain purchasers listed therein",
"Cover Page Interactive Data File (embedded within the Inline XBRL document)",
"Consulting Agreement, by and between Aadi Bioscience, Inc. and Danforth Advisors, LLC (filed herewith)",
"Aadi Bioscience, Inc. 2021 Equity Incentive Plan (filed herewith)",
"Form of Stock Option Agreement under the Aadi Bioscience, Inc. 2021 Equity Incentive Plan (filed herewith)",
"2021 Employee Stock Purchase Plan (filed herewith)",
"Aadi Bioscience, Inc. 2014 Equity Incentive Plan (filed herewith)"
08/23/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Asset Purchase Agreement dated August 17, 2021, by and between Aerpio Pharmaceuticals, Inc. and EyePoint Pharmaceuticals, Inc. (filed herewith)"
08/17/2021 8-K Quarterly results
08/11/2021 8-K Quarterly results
07/26/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
05/20/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
04/01/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment to Transition Services Agreement, entered into on April 1, 2021, by and between Aerpio Pharmaceuticals, Inc. and Kevin G. Peters",
"Consulting Services Agreement, entered into on April 1, 2021, by and between Aerpio Pharmaceuticals, Inc. and Kevin G. Peters"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy